Mark A Pearson
Overview
Explore the profile of Mark A Pearson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
606
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilding B, Woelflingseder L, Baum A, Chylinski K, Vainorius G, Gibson N, et al.
Cancer Discov
. 2024 Sep;
15(1):119-138.
PMID: 39248702
Mutations in ERBB2 (encoding HER2) occur in 2% to 4% of non-small cell lung cancer (NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for treating other HER2-dependent cancers,...
2.
Lipp J, Wang L, Yang H, Yao F, Harrer N, Muller S, et al.
Oncoimmunology
. 2022 Feb;
11(1):2019466.
PMID: 35154905
Antibody-mediated cancer immunotherapy targets inhibitory surface molecules, such as PD1, PD-L1, and CTLA-4, aiming to re-invigorate dysfunctional T cells. We purified and characterized tumor-infiltrating lymphocytes (TILs) and their patient-matched non-tumor...
3.
van der Lelij P, Newman J, Lieb S, Jude J, Katis V, Hoffmann T, et al.
Life Sci Alliance
. 2020 May;
3(7).
PMID: 32467316
The cohesin subunit has emerged as a recurrently inactivated tumor suppressor in human cancers. Using candidate approaches, recent studies have revealed a synthetic lethal interaction between and its paralog To...
4.
Ehrenhofer-Wolfer K, Puchner T, Schwarz C, Rippka J, Blaha-Ostermann S, Strobl U, et al.
Sci Rep
. 2019 Aug;
9(1):11661.
PMID: 31406271
SMARCA4/BRG1 and SMARCA2/BRM, the two mutually exclusive catalytic subunits of the BAF complex, display a well-established synthetic lethal relationship in SMARCA4-deficient cancers. Using CRISPR-Cas9 screening, we identify SMARCA4 as a...
5.
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
Lieb S, Blaha-Ostermann S, Kamper E, Rippka J, Schwarz C, Ehrenhofer-Wolfer K, et al.
Elife
. 2019 Mar;
8.
PMID: 30910006
Targeted cancer therapy is based on exploiting selective dependencies of tumor cells. By leveraging recent functional screening data of cancer cell lines we identify Werner syndrome helicase (WRN) as a...
6.
van der Lelij P, Lieb S, Jude J, Wutz G, Santos C, Falkenberg K, et al.
Elife
. 2017 Jul;
6.
PMID: 28691904
Recent genome analyses have identified recurrent mutations in the cohesin complex in a wide range of human cancers. Here we demonstrate that the most frequently mutated subunit of the cohesin...
7.
Seccombe L, Jenkins C, Rogers P, Pearson M, Peters M
Eur Respir J
. 2013 Mar;
41(3):760-2.
PMID: 23456938
No abstract available.
8.
Kaneda A, Wang C, Cheong R, Timp W, Onyango P, Wen B, et al.
Proc Natl Acad Sci U S A
. 2007 Dec;
104(52):20926-31.
PMID: 18087038
Loss of imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to abnormal activation of the normally silent maternal allele, is a common human epigenetic population variant associated with...
9.
Giuliani J, Gjersing E, Chinn S, Jones T, Wilson T, Alviso C, et al.
J Phys Chem B
. 2007 Oct;
111(45):12977-84.
PMID: 17958412
Thermal degradation of a filled, cross-linked siloxane material synthesized from poly(dimethylsiloxane) chains of three different average molecular weights and with two different cross-linking species has been studied by (1)H multiple...
10.
Pearson M, Fabbro D
Expert Rev Anticancer Ther
. 2004 Dec;
4(6):1113-24.
PMID: 15606337
The fundamental role of kinases in cancer progression has promoted the development of a plethora of therapeutic inhibitors. Despite the promise of effective treatment with little associated toxicity, the clinical...